Heart Safety
Attorney
(866) 735-1102 Ext 415
Recently, reviews of dozens of studies involving hundred of thousands of patients revealed most patients should try naproxen also known as Aleve for pain. According to experts "it doesn't raise hart attack or stroke risk and naproxen is less expensive; has been around of years; and is available as an over the counter medication
There is a drawback however it can irritate the stomach. Dr. Steven Nissen, head of cardiology at the Cleveland Clinic and president of the American College of Cardiology, states: "I don't think we should start with naproxen in the vast majority of cases. It's about balancing the cardiovascular and gastrointestinal risk."
Aside from the good news, two studies raised concerns about diclofenac; and an anti-inflammatory drug sold as Voltaren and Cataflam. These carry a high risk of heart attack or stroke as Vioxx. Additionally, the studies also provided Vioxx poses more of a danger to the heart and kidneys. Vioxx was pulled off the market in September 2004.
Hartford Medical School's group study advises patients to wait seven years before trying a new drug, as safety problems normally become clear.
Those especially worried about safety could try pain ointments first. If they don't help, Dr. Richard Jermyn, director of the University Pain Care Center suggest Tylenol, then naproxen or ibuprofen before resorting to Celebrex.
Researchers at the University of Newcastle in Australia recommend a regulation review of diclofenac about keeping this drug on the market. The FDA's response is that the new information does not warrant a change in regulations of NASIDs. Many U.S. patients have switched to Mobic, made by Boehringer Ingelheim Corp
A second review by researchers at Harvard's medical and public health schools and Brigham and Women's Hospital, which focused on less-publicized problems. Their findings revealed Vioxx increased the risk of kidney problems about 50 percent and potentially deadly heart rhythms nearly tripled. They did not find that Celebrex raised those risks.
16,000 lawsuits have already been filed against Merck. The results of this study could add more case to Merck's ongoing headache. Additionally, the review of cardiovascular studies found increase in heart attack and stroke risk to be right away at doses above 25 milligrams per day, not after 18 months as Merck has been arguing.
">http://www.msnbc.msn.com/id/14805300/from/ET/Older painkiller safest for your heart,/a.article">